🇺🇸 FDA
Patent

US 11685918

Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K47/549

Quick answer

US patent 11685918 (Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/713, A61K47/549, A61K47/56, A61P